Massive Acquisition: Lucy Scientific (LSDI) Announces Acquisition of SANA-013

Lucy Scientific manufactures therapeutic psychedelics and made a huge announcement, we will get to that soon.

First, let’s go over the acquisition:

March 21, 2023

Lucy Scientific LSDI entered into a definitive asset purchase agreement with Wesana Health Holdings Inc. (“Wesana”).

Lucy has agreed to acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, and Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies. 

The aggregate consideration comprises 1,000,000 shares of common stock and $570,000 in cash. 

The shares will be subject to a lock-up agreement whereby half of the shares will be released 9 months from closing, and other half will be released 14 months from closing. The transaction is also subject to Wesana’s shareholder approval and is expected to close in Q2 2023.

The Global Psychedelics Market Is Expected To Reach almost $100 BN By 2029 Full Article

That is larger than the cannabis market segment, without a market leader.

Lucy Scientific has made some serious steps toward possibly dominating the market.

This is exciting investors, it is a second chance at the cannabis boom but bigger.

In case, you need a reminder of how crazy that ride was, the market grew by 250% in less than a year.

Breaking News:

Mar 23, 2023

Announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.

The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.

Lucy Scientific will produce Mindful with High Times, through a strategic partnership with Hightimes Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times’ websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts.

With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025.

Full Press Release HERE.

Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential, concentrating on IPOs and we have uncovered some interesting data on LSDI.

Our research reports have uncovered some of the largest breakout stock alerts year after year.

LSDI may even be the best yet. So put us to the test and put it on your watchlist.

We stand by our alerts, our 2023 alert tracker provides transparency. Click HERE

Top 3 catalysts that could send LSDI up 127%++ in the next month:

#1 The Chart

#2 IPOs Offer A Significant Upside Potential

#3 The Market Could Be As Big As Coffee

Lucy’s Other Explosive Catalysts

  • Recent news has has not been covered by major financial news outlets, creating a unique opportunity.
  • Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin. Press Release
  • Files Amendment with Health Canada to Expand its List of Controlled Substances to Include Cocaine and Heroin Press Release

Wait until you see what we have uncovered!

Major Psychedelic Announcements:

2019: May 9th

Denver, Colorado became the first city in the United States to decriminalize the cultivation, possession and use of psilocybin mushrooms.

2019: June 5th

Oakland California decriminalized the cultivation, possession and use of plants or fungi containing psychedelic compounds including DMT, ibogaine, mescaline and psilocybin.

2019: September 4th

Johns Hopkins launched the Center for Psychedelic and Consciousness Research.  The center’s director, Roland Griffiths, said that researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, learning, memory, and biological markers of health.

2019: November 22nd

The Food and Drug Administration granted Breakthrough Therapy designation to the Usona Institute for its psilocybin therapy for major depressive disorder.  Usona’s phase 2 clinical trials will include 80 volunteers at seven sites around the U.S. 

2020: October 22nd

In Vancouver, Canada Numinus Wellness Inc. harvested the first legal flush of psilocybin mushrooms by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s License.

2021: October 18th

Johns Hopkins Medicine was awarded a $3.9 million grant by the National Institutes of Health (NIH) for clinical research on psilocybin-assisted psychotherapy to treat tobacco addiction.

Let’s take a closer look at Lucy LSDI.

2023: March 23

Announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.

The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.

Lucy Scientific Discovery Company Summary

Company Name: Lucy Scientific Discovery

Ticker: LSDI

Exchange: NASDAQ

Website: https://www.lucyscientific.com/

Lucy’s Company Summary:

Lucy Scientific Discovery Inc. [NASDAQ:LSDI] an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry.

Lucy maintains a Controlled Drugs and Substances Dealer’s License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer’s License, that was issued to Lucy by Health Canada’s Office of Controlled Substances.

This Dealer’s License authorizes the Company to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.

Before we review #1 Catalyst, their technology suite, let’s review how the catalysts above could generate parabolic growth.

As mentioned above, Lucy Scientific Discovery trades on the NASDAQ as an IPO, which indicates the incredible upside potential.

Let’s jump into the top 3 now.

First things first, the indicator above on the short term is Bullish, so what are you waiting on?

Pull up LSDI and start your research before it’s too late.

Next, the chart is bullish coming off a bearish move into a consolidation pattern.

The lows are getting higher and the highs are getting higher, so we are feeling really good about LSDI for next week!

The chart has clearly broken out and is creating a bullish trend line. Start your research now before it is too late, just like the green boom.

Facebook META acted the same way as most IPOs with hype. They get overbought, they pull back and then run like mad!

Lucy is following that same pattern and we believe it has created a bottom and has broken out clearly in the above image.

Look at what Motley Fool wrote about the massive opportunity FB provided, “The stock was offered at $38 per share via the IPO. Let’s assume you bought 132 shares for a total of $5,016 on May 18, 2012, and held all the way through to today. At today’s price of around $191 per share, those 132 shares would be worth $25,212, resulting in a market-beating five-bagger.”

Just like the cannabis boom, and Facebooks IPO, traders are being handed another possible monumental opportunity.

Before we go over the news, take a look at what Grand View Research published.

Mar 17, 2023

Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities

VICTORIA, British Columbia and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company, announced today that it has partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies.

The US government has been taking proactive measures to secure the domestic drug supply from international risks, given the severe shortages of key pharmaceutical drugs, nutraceuticals, and even baby formula in recent years. As part of this effort, multiple federal agencies across the US and Canada made funding available to support domestic drug manufacturing.

Press Release

Mar 8, 2023

Update after Discussions with Health Canada; Lucy Scientific Discovery Files Amendment with Health Canada to Expand its List of Controlled Substances to Include Cocaine and Heroin; This Expansion Represents an Effort to Supply Harm Reduction Programs Around the World

VICTORIA, British Columbia, March 8, 2023 — Lucy Scientific Discovery Inc. (“Lucy” or the “Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychotropics-based medicines industry, announced an amendment to its current Dealer’s License with Health Canada, held by its wholly owned subsidiary LSDI Manufacturing Inc., to add cocaine and heroin, among others to the list of approved substances that it is authorized to manufacture.

The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options. Currently, Lucy focuses on the development of psychedelic drugs for research purposes and hopes to supply harm reduction programs in the future. The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B.

Press Release

Mar 8, 2023

Update after Discussions with Health Canada; Lucy Scientific Discovery Files Amendment with Health Canada to Expand its List of Controlled Substances to Include Cocaine and Heroin; This Expansion Represents an Effort to Supply Harm Reduction Programs Around the World

VICTORIA, British Columbia, March 8, 2023 — Lucy Scientific Discovery Inc. (“Lucy” or the “Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychotropics-based medicines industry, announced an amendment to its current Dealer’s License with Health Canada, held by its wholly owned subsidiary LSDI Manufacturing Inc., to add cocaine and heroin, among others to the list of approved substances that it is authorized to manufacture.

The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options. Currently, Lucy focuses on the development of psychedelic drugs for research purposes and hopes to supply harm reduction programs in the future. The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B.

“We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. “It’s time to realize that the failed war on drugs has caused additional harm to the masses worldwide, and harm reduction programs will lead to less death and more treatment options in the long term.”

Press Release

Condensed Disclaimer

Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $350,000 from Lucy Scientific Discovery Inc. for profiling LSDI. We own ZERO shares in LSDI.

FULL DISCLAIMER